Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Pelvic Radiation for Endometrial Cancer
NCT00515073Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2001
- Primary completion
- May 2013
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection in Endometrial Serous Carcinoma (ESC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 5 years, Local Control and 2 more. Started Apr 2001; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
Endometrial Serous Carcinoma (ESC)
Beyond the preview
Go deeper on NCT00515073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515073.